Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 2/20 | 0.38 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.35 |
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.34 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.69 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | DUSP5 | Q16690 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516471 | 1.00 | NR4A1 (0.69) | NR4A1AURKAAURKBTTRDUSP5 | |
| SCHEMBL30913230 | 0.90 | NR4A1 (0.66) | NR4A1AURKAAURKBTTRDUSP5 | |
| SCHEMBL28747694 | 0.85 | NR4A1 (0.94) | NR4A1AURKAAURKBTTRDUSP5 | |
| SCHEMBL29532393 | 0.81 | NR4A1 (0.51) | NR4A1AURKAAURKBTTRDUSP5 | |
| SCHEMBL6615466 | 0.81 | NR4A1 (0.51) | NR4A1AURKAAURKBTTRDUSP5 | |
| SCHEMBL2951288 | 0.79 | TTR (0.63) | NR4A1TTRALDH1A1CYP3A4HPGD | |
| SCHEMBL7179151 | 0.79 | NR4A1 (0.56) | NR4A1TTRTHRBALDH1A1CYP3A4 | |
| SCHEMBL30742565 | 0.79 | NR4A1 (0.56) | NR4A1TTRTHRBALDH1A1CYP3A4 | |
| SCHEMBL2093555 | 0.79 | NR4A1 (0.56) | NR4A1TTRTHRBALDH1A1CYP3A4 | |
| SCHEMBL29354786 | 0.79 | NR4A1 (0.56) | NR4A1TTRTHRBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221408-A1 | COMPOSITION | EARTH CORPORATION (JP) | 2025-07-10 | — | — | US | disclosed |
| EP-4473837-A1 | COMPOSITION | Earth Corporation (JP) | 2024-12-11 | — | — | EP | disclosed |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | ACENET INC. (JP) | 2024-01-04 | — | — | US | disclosed |
| WO-2023190598-A1 | COMPOSITION | アース製薬株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230263710-A1 | ORAL CARE AGENT | OSAKA UNIVERSITY (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-4230042-A1 | ANTIPATHOGENIC DRUG, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN PROCESSING DEVICE, METHOD FOR PRODUCING ANTIPATHOGENIC DRUG, ANTIBACTERIAL METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN PROCESSING METHOD | Acenet Inc. (JP) | 2023-08-23 | — | — | EP | disclosed |
| CN-116322332-A | Antipathogenic agent, antibacterial agent, antiviral agent, pathogen treatment device, method for producing antipathogenic agent, antibacterial method, virus inactivation method, and pathogen treatment method | 株式会社ACENET | 2023-06-23 | — | — | CN | disclosed |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-06-15 | — | — | US | disclosed |
| CN-116157109-A | Oral pharmaceutical preparation | 国立大学法人大阪大学 | 2023-05-23 | — | — | CN | disclosed |
| EP-4147703-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-03-15 | — | — | EP | disclosed |
| US-20180151805-A1 | CHARGE-TRANSPORTING VARNISH, AND ORGANIC ELECTROLUMINESCENT ELEMENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-05-31 | — | — | US | disclosed |
| EP-3309851-A1 | CHARGE-TRANSPORTING VARNISH AND ORGANIC ELECTROLUMINESCENT ELEMENT | Nissan Chemical Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | disclosed |
| EP-3306692-A1 | CHARGE-TRANSPORTING VARNISH, AND ORGANIC ELECTROLUMINESCENT ELEMENT | Nissan Chemical Industries, Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| EP-3121163-A1 | OLIGOANILINE DERIVATIVE, CHARGE-TRANSPORTING VARNISH, AND ORGANIC ELECTROLUMINESCENT ELEMENT | Nissan Chemical Industries, Ltd. (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-20160248018-A1 | ARYLSULFONIC ACID COMPOUND, USE THEREOF, AND METHOD FOR PRODUCING ARYLSULFONIC ACID COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-3056484-A1 | ARYLSULFONIC ACID COMPOUND, USE THEREOF, AND METHOD FOR PRODUCING ARYLSULFONIC ACID COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-4229584-A | Ureylenebis(anionic substituted phenylene carbonyl)imino naphthalene sulfonic acids and naphthalene carboxylic acids and their salts | AMERICAN CYANAMID COMPANY (US) | 1980-10-21 | — | — | US | disclosed |
| US-4177209-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1979-12-04 | — | — | US | disclosed |
| US-4129590-A | INHIBITORS OF THE COMPLEMENT SYSTEM | AMERICAN CYANAMID COMPANY (US) | 1978-12-12 | — | — | US | disclosed |
| US-4027038-A | NAPHTHALENEDISULFONIC ACID UREIDES | AMERICAN CYANAMID COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263710-A1 | ORAL CARE AGENT | TAS2R39, TAS2R40, TAS2R45 | THRB 4465/4885CA1 2268/4885CA2 1770/4885 |
| US-20160248018-A1 | ARYLSULFONIC ACID COMPOUND, USE THEREOF, AND METHOD FOR PRODUCING ARYLSULFONIC ACID COMPOUND | ARSA, SULT2A1, SULT1A1 | THRB 1389/4885CA1 3566/4885CA2 2435/4885 |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | EPCAM, EGFR, MUC1 | THRB 3888/4885CA1 83/4885CA2 78/4885 |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | EIF2AK2, HAO2, ZC3HAV1 | THRB 1079/4885CA1 3911/4885CA2 2225/4885 |
| US-20250221408-A1 | COMPOSITION | GGPS1, PGGT1B, HBG2 | THRB 2584/4885CA1 2324/4885CA2 2673/4885 |
| US-20180151805-A1 | CHARGE-TRANSPORTING VARNISH, AND ORGANIC ELECTROLUMINESCENT ELEMENT | SLCO4C1, SLCO2A1, SLCO1A2 | THRB 2284/4885CA1 1367/4885CA2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.